Goldman Sachs Group Inc Bio N Tech Se Put Options Transaction History

Goldman Sachs Group Inc

10 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$78.36 - $124.66 $1.25 Million - $1.99 Million	16,000 Added 94.12%	33,000 $3.92 Million
Q2 2024 Aug 13, 2024	BUY	$80.36 - $102.87 $891,996 - $1.14 Million	11,100 Added 188.14%	17,000 $1.37 Million
Q1 2024 May 15, 2024	BUY	$88.96 - $112.35 $524,864 - $662,865	5,900 New	5,900 $544,000
Q1 2023 May 14, 2024	BUY	$122.57 - $153.67 $2.11 Million - $2.64 Million	17,200 Added 614.29%	20,000 $2.49 Million
Q1 2023 May 11, 2023	BUY	$122.57 - $153.67 $2.11 Million - $2.64 Million	17,200 Added 614.29%	20,000 $2.49 Million
Q2 2022 May 14, 2024	BUY	$123.25 - $186.24 $345,100 - $521,472	2,800 New	2,800 $417,000
Q2 2022 Aug 15, 2022	SELL	$123.25 - $186.24 $22.5 Million - $34 Million	-182,800 Reduced 98.49%	2,800 $417,000
Q1 2022 May 16, 2022	BUY	$126.25 - $231.85 $10.3 Million - $18.9 Million	81,500 Added 78.29%	185,600 $31.7 Million
Q4 2021 Feb 14, 2022	BUY	$216.64 - $362.52 $16.1 Million - $26.9 Million	74,100 Added 247.0%	104,100 $26.8 Million
Q3 2021 Nov 10, 2021	BUY	$205.93 - $447.23 $6.18 Million - $13.4 Million	30,000 New	30,000 $8.19 Million

357

38.3M

2.45M

2.29M

Ticker BNTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 242,684,992
Market Cap $27.3B
Description
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.